Author of

• 12592

  +

  P3.10 - Poster Session 3 - Chemotherapy (ID 210)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12624

    +

    P3.10-032 - Efficiency and safety of erlotinib in the second and the further lines of treatment for patients (caucasian etnic) with advanced, non-small-cell lung cancer in Eastern Slovakia. (ID 1973)

    09:30 - 09:30  |  Author(s): B. Ziarna
    • Abstract

    Background
    Erlotinib is indicated in first line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR positive mutation, then in maintenance treatment of patients with NSCLC, and in second line after failure of at least one chemotherapy regimen. Its efficiency is comparable with chemotherapy, but erlotinib has better adverse-event profile, it is better tolerated, with no haematological toxicity.

    Methods
    We evaluated data of 154 patients treated in 5 hospitals in Eastern Slovakia between January 01,2008, and October 31,2012. The primary endpoint was overall survival (OS) and secondary endpoints were progression-free survival (PFS) overall response and safety. Statistical analysis was performed using Kaplan Meier method and logrank test. The overall population had a median age of 63,6 years (range +-10,7 year).The group included higher percentage of: males (70,8%); patients with squamous-cell histology (52%); patients with stage IV disease 85,7% and patients with ECOG performance status O-1 53%. In total 62 % patients were treated in second-line and 38% in further lines of treatment.

    Results
    Median overall survival (OS) was 8,3 months. In multivariate analysis, significantly better OS was in group of patients with stage IIIB vs, IV (p =0.033), with PS 0-1 vs. 2 ( 0.011) and previous response on chemotherapy (p=0.011). There was no significant difference in multivariate analysis caused by histological subtype, smoking status and sex. Median of PFS was 4,96 months. Response rate (CR +PR) was observed in 24% of population (mainly PR), but clinical benefit was observed in 70% of patients. Most common toxicity of erlotinib treatment was skin rash (70%) but grade III and IV was only in 4 % of cases. Grade III and IV diarrhea was observed in 1,3 % of patients.

    Conclusion
    Erlotinib is acceptable treatment (with acceptable OS,PSF and toxicity profile) for patients either with unknown EGFR mutation status or patients unsuitable for chemotherapy.